Navigation Links
Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
Date:4/19/2011

SCHAUMBURG, Ill., April 20, 2011 /PRNewswire/ -- Sagent Pharmaceuticals (Nasdaq: SGNT) announced the upsizing and pricing of its initial public offering.  The size of the offering has been increased from the previously announced 5,000,000 shares of common stock to 5,750,000 shares of common stock at a price to the public of $16.00 per share. The shares are scheduled to begin trading on The NASDAQ Global Market on April 20, 2011 under the ticker symbol "SGNT."  The underwriters have a 30-day option to purchase up to an additional 862,500 shares at the initial public offering price. The offering is expected to close on April 26, 2011.

Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering. Needham & Company, LLC and RBC Capital Markets are acting as the co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 19, 2011. The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by e-mail at prospectus@morganstanley.com; from BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department, or by e-mail at dg.prospectus_requests@baml.com; or from Jefferies, 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.


'/>"/>
SOURCE Sagent Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
10. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
11. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of ... the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” ... offers a 70% tax credit to individuals and corporations which donate directly to a ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only ... majority of skin cancer deaths. More than 10,000 people are expected to die of melanoma ... 62, it is the one of the most commonly diagnosed cancers in young women. A ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):